|
|
Discovery & Pipeline.
Thrombotargets has developed and adapted to High Throughput Screening a new family of biological assays capable to simultaneously quantify clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms, , Thrombotargets is continuously creating a novel and promising pipeline of drug candidates.
|